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Abstract
Pharmaceutical risk-sharing arrangements have emerged as a reasonable tool to promote sustainable access to innovative 
medicines with uncertain clinical evidence and/or economic impact from the payer perspective. These funding mechanisms 
pose an alternative option to the traditional fixed-price methods and are intended to align the price of medication with the 
value delivered in treating patients, balancing clinical need with affordability in the face of increasing therapeutic innovation 
and ever-tight budgets. The Catalan Health Service (CatSalut) has set up a systematic, traceable, and transparent methodology 
for the design and implementation of risk-sharing arrangements and 15 of such access schemes have been successfully imple-
mented until December 2019. Our experience has acknowledged the need for a robust study design, appropriate financial, 
technical, and administrative resources, and strong stakeholder commitment and communication as critical to the success of 
risk-sharing arrangements. While the experience in Catalonia has been positive and has served to highlight the potential of 
such schemes in tackling public health policy concerns, this exchange can often be undermined by the lack of transparency 
surrounding risk-sharing arrangements and the fact that the literature related to their methodology, implementation, and 
impact is scarce. Further studies should be conducted and shared to address this obstacle.
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Key Points 
Pharmaceutical risk-sharing arrangements (RSAs) pose 
an alternative option to the traditional fixed-price meth-
ods and are intended to align the price of medication 
with the value delivered in treating patients, balanc-
ing clinical need with affordability in situations where 
uncertainties over a certain medicine are present.
This study provides an example on how to set up a sys-
tematic, traceable, and transparent methodology for the 
design and implementation of RSAs.
This study could inform other policy makers willing 
to set up a RSA methodology in their geographies, or 
provide new ideas for existing RSA processes.
1  Background
Each year, a high number of innovative medicines are 
approved by the European Commission based on the 
European Medicines Agency’s recommendation, trig-
gering a wave of pricing and reimbursement decisions 
in each member state [1]. For Spain in particular, the 
pricing and reimbursement process and the inclusion of 
new drugs in the National Health System pharmaceutical 
repository are covered by the Spanish Ministry of Health 
[2]. However, because of the decentralized nature of the 
Spanish healthcare model, most budgetary, planning, and 
operative aspects of healthcare provision are managed 
by regional governments. Catalonia is the second largest 
region in Spain, with 7.7 million inhabitants (16.3% of 
the Spanish population) and has a network of 65 public 
hospitals [3]. The Catalan Health Service (Servei Català 
de la Salut, henceforth, CatSalut) is the entity that ensures 
public access to the National Health System services in 
Catalonia. CatSalut operates through a multi-provider sys-
tem known as the Integrated Public Healthcare System 
of Catalonia (SISCAT, its acronym in Catalan), accord-
ing to the principles of equity, quality, and sustainability, 
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by distributing and balancing resources according to the 
diverse needs of the population [4]. One of the responsi-
bilities of CatSalut is to promote the rational use of drugs 
and ensure an efficient access to medicines across the 
Catalan territory.
Since the 1990s, many public healthcare systems world-
wide have been assessing and implementing alternative 
funding mechanisms to the traditional fixed-price methods, 
such as pharmaceutical risk-sharing arrangements (RSAs), 
to accommodate access to novel medicines where there are 
uncertainties regarding their clinical effect on patients or 
their burden to health systems [5–7]. Risk-sharing arrange-
ments are contracting schemes between healthcare pay-
ers and marketing authorization holders (MAHs) that link 
the access and cost of a therapeutic innovation to specific 
conditions of use or outcomes in clinical practice [5, 6]. 
Therefore, the risks and uncertainties arising from public 
coverage are shared between the payer and the MAH [5–8]. 
The use of such arrangements has considerably increased 
over time in response to the increasing cost of innovation, 
particularly in the fields of oncology, neurology, and rheu-
matology [6], and the need to contain healthcare budgets 
while timely addressing unmet needs and ensuring patients 
access to novel therapies [8, 9].
According to the Professional Society for Health Eco-
nomics and Outcomes Research [10], RSAs are largely 
divided into performance-based risk-sharing arrangements 
(PBRSAs) and cost-sharing arrangements (CSAs). Perfor-
mance-based risk-sharing arrangements are broken down 
into (a) coverage with evidence development schemes, 
whose goal is to provide coverage while the evidence 
(i.e., additional population-level data) is developed to 
support continued or modified coverage and (b) perfor-
mance-linked reimbursement schemes (PLRSs), whose 
goal is to manage utilization, aiming to control the cost 
effectiveness (CE) of a new technology in the real world 
[10]. Performance-linked reimbursement schemes include 
outcomes and money back guarantees (i.e., payment for 
responders only, refunds for non-responders), conditional 
treatment continuation (i.e., linked to intermediate end-
points), and/or payments related to the process of care 
(e.g., linked to compliance with clinical guidelines or on 
the basis of a biomarker) [10]. Cost-sharing arrangements 
include budget capping and/or utilization capping, variable 
or fixed discounts, and price-volume schemes [10].
CatSalut is guided by the strategic objectives and policies 
included in Catalonia’s Health Plan, which in 2011 intro-
duced flexible reimbursement systems for medicines linked 
to the achievement of agreed-upon results [11, 12]. This led 
to a guided and gradual introduction of demo experiences 
(i.e., pilot or hospital-initiated RSAs) to acquire practi-
cal insight on the RSA implementation process. The first 
hospital-initiated RSA enrolled 41 patients and was signed 
in 2011 by the Catalan Institute of Oncology and a MAH 
for the introduction of a targeted therapy for the treatment 
of advanced non-small-cell lung cancer [13]. From 2011 
to 2015, more than 20 hospitals signed 12 independent 
hospital-initiated RSAs (ten in oncohematology and two 
in rheumatology). These were led by the hospitals them-
selves and self-managed in terms of clinical and financial 
assessment of the schemes, including administrative tasks 
such as the issuing of payments and refunds. This learn-
ing phase was critical to CatSalut and SISCAT to obtain 
valuable knowledge on contract elaboration, assess capabil-
ity of existing databases to monitor drug use and cost, and 
shape stakeholder alignment and communication. In 2016, 
CatSalut took the lead from hospitals in the broader devel-
opment, management, and implementation of RSAs for all 
SISCAT hospitals. A new centralized working dynamic was 
introduced, and a multidisciplinary working group for the 
development and management of RSAs was created. Risk-
sharing arrangements were supported by a single contract 
between MAHs and CatSalut. Participation was automatic 
and mandatory for financial arrangements (i.e., CSAs), while 
participation in PBRSAs was initially bound to adhesion 
contracts signed between each reference hospital (i.e., hos-
pital with the medical expertise required for the condition 
included in the PBRSA) and the MAH on a voluntary basis. 
However, in 2020, after a period where hospitals adapted to 
the collection of health outcomes, CatSalut made the par-
ticipation of reference hospitals in PBRSAs automatic and 
mandatory, eliminating the need for adhesion contracts and 
making the process consistent between CSAs and PBRSAs. 
To systematically decide on the appropriateness of RSAs 
and settle the basis for their implementation through a robust 
step-by-step decision-making process, CatSalut developed a 
specific RSA guideline [14] in 2014, with the participation 
of academics and experts.
Despite the rising popularity of RSAs and the increas-
ing availability of primary market research studies [9, 15, 
16], reviews [6, 7, 17], and best-practice guidelines for their 
implementation [10], there are a very limited number of 
publications assessing the methodology, implementation, 
and long-term value and impact of RSAs worldwide [8, 13], 
which makes it difficult to learn from these experiences. The 
aim of this article is to describe the broad RSA process in 
Catalonia and to share our experience.
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2  Drug Assessment, Selection, 
and Development of an Appropriate RSA
2.1  Drug Assessment and Identification 
of Uncertainties
In 2008, CatSalut established its own drug appraisal pro-
gram (PHF, its acronym in Catalan) [18], with the aim of 
guaranteeing equitable access to innovative medicines across 
the Catalan territory in accordance with the principles of 
rational drug use, and cognizant of the availability and opti-
mization of resources. The PHF comprises two advisory 
councils, one for hospital outpatient drugs and one for pri-
mary care drugs (CAMH and CAMAPCE, respectively, their 
acronym in Catalan), and a decision-making commission 
(CFT-SISCAT, its acronym in Catalan). The three expert 
panels include members with different professional and clin-
ical backgrounds (i.e., regional and hospital payers, hospital 
pharmacists, clinicians, health economists, bioethics experts, 
and patient representatives) to provide a holistic and multi-
disciplinary approach to drug assessment. Each panel counts 
on two representatives from different patient associations to 
ensure the patients’ voice is heard at each step of the drug 
appraisal process. These individuals have been trained on 
administration procedures and their nomination is proposed 
by the Patient Advisory Council of Catalonia’s Department 
of Health, which is the official body that represents patient 
organizations in front of the Catalan Administration [19]. 
Patient representatives provide their considerations on the 
clinical value of innovations at each drug appraisal but can-
not execute their vote on appraisals concerning their own 
disease. Considerations of patients affected by the condition 
under study, including their medical and non-medical needs, 
expectations for new treatments, and the relevance that some 
of the results reported in clinical trials may have in their 
daily lives are collected through anonymous interviews con-
ducted by evaluators for each drug appraisal. The different 
expert panel members are required to renew or ratify their 
positions every 3 years [18].
Based on the recommendations from the advisory coun-
cils, the CFT-SISCAT assesses the added value of innova-
tive drugs and, particularly for hospital outpatient drugs, 
defines their conditions of use and access across the region 
in accordance to the medicine’s clinical performance and 
cost considerations discussed during drug assessment [18]. 
Currently, there are three possible outcomes to this process: 
(1) use under specific clinical criteria defined by the CFT-
SISCAT, which can be aligned with or stricter than those of 
the authorized indication; (2) use under individual authori-
zation, in which case treatment has to be approved by an 
expert committee case by case; or (3) exceptional use, if 
there is unfavorable or insufficient evidence to recommend 
its use. Drugs granted exceptional use—19 of 280 drugs 
appraised by the PHF in their respective indications until 
December 2019 (6.8%)—cannot be invoiced through regular 
channels (i.e., CatSalut does not reimburse these treatments 
to hospitals choosing to use these drugs), and therefore they 
have to be funded at the expense of the hospital’s budget. 
The verdict of the CFT-SISCAT also stipulates the need for 
a managed access under a RSA where appropriate, which 
since 2020 has been linked to the automatic applicability of 
these schemes across the region.
The decision to establish a RSA for a particular drug in a 
given indication always arises from uncertainties identified 
by the PHF during the drug appraisal process. These uncer-
tainties may be linked to clinical parameters (i.e., efficacy, 
effectiveness, safety) or economic parameters (i.e., budget 
impact [BI], CE). Clinical uncertainty is often related to 
the study design, clinical trial data, and its robustness, and 
alignment with real clinical practice. Similarly, financial 
uncertainty is often related to difficult estimates of the tar-
get population and BI, possible indication extensions, and/
or lack of a fully established drug regimen and duration, 
among others (Table 1). CatSalut technicians assess the 
quality of economic evaluations conducted by the manufac-
turer as part of the routine exchange of information between 
CatSalut and the MAH prior to the medicine’s appraisal by 
using CatSalut’s Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) checklists [20]. Currently, 
the scope of RSAs in Catalonia is exclusively focused on 
hospital outpatient drugs because of their correlation with 
higher BIs and innovation.
2.2  Working Group for the Development 
and Management of RSAs
The group is composed of CatSalut professionals and rep-
resentatives from healthcare providers, including clini-
cians, hospital pharmacists, regional and hospital payers, 
and health economists. Together, these members discuss 
the uncertainties to be tackled, as proposed by the CFT-
SISCAT, and define the most appropriate type of RSA in 
each case according to CatSalut’s guideline for RSAs [14]. 
The guideline incorporates questionnaires to assess differ-
ent clinical and financial dimensions, with items assessed 
according to relevance and level of uncertainty, including 
potential scenario mapping to establish the optimal RSA 
scheme to use in a given situation. For uncertainties con-
cerning health outcomes, the proposed model is generally 
a PBRSA, to limit and share the risk of these uncertainties 
over time. Conversely, for uncertainties concerning financial 
outcomes, either associated with the treatment itself or the 
estimated target population, the proposed model is typically 
a CSA or conventional payment with a simple discount, to 
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limit and share the risk of an unexpected growth of BI, with 
potential restrictions to patient subgroups if there is strong 
evidence to support a greater drug value for a defined sub-
group (Table 2). With regard to PBRSAs, clinicians with 
experience in the disease area are always invited ad hoc to 
share their expertise with the working group and support the 
proposals, by ensuring that the proposed clinical objectives, 
treatment response criteria, and treatment follow-up are con-
sistent with daily clinical practice and available evidence. In 
contrast, for CSAs, ad hoc clinicians are only consulted to 
validate clinical aspects of the contract in the case of doubt 
(e.g., eligible criteria, number of cases, patient subgroups).
Once a customized proposal is agreed by the members 
of the working group, CatSalut presents a formal proposal 
to the MAH. At this point, terms and conditions are negoti-
ated with the MAH for a fixed period of time that is set on a 
case-by-case basis (usually between 3 and 4 months), during 
which amendments can be made by both of the two parties 
until a final agreement is reached on both ends. Between 
2016 and 2019, 25.0% of the proposals were dismissed by 
MAHs, where a mutual agreement could not be reached. 
Eventually, this proposition, agreed upon by the working 
group and the MAH, is presented to the CFT-SISCAT for 
endorsement (Fig. 1).
2.3  Agreement Formalization: Legally Binding 
Contracts
Contracts containing the agreed terms and conditions are 
formalized by CatSalut and the respective MAH’s legal 
departments, and then signed by representatives of all parties 
involved; usually CatSalut’s Director and a top-level execu-
tive from the respective MAH. Contracts always include: (a) 
administrative criteria (i.e. contract validity period, contract 
renewal options), (b) clinical criteria (i.e., chosen medicine, 
indication, inclusion and exclusion criteria, treatment fol-
low-up periods, variables and methods to measure treatment 
response, definition of treatment response), (c) economic 
conditions (i.e., conditions for rebates or discounts, due 
dates for refunds), (d) legal criteria (i.e., transparency, intel-
lectual property, confidentiality), and (e) additional infor-
mation regarding implementation steps (i.e., data sources, 
monitoring process including timeline for data analysis, typi-
cally every 12 months, matching calendar years, frequency 
of communication between CatSalut and the MAH).
Table 1  Uncertainty type, scope, and considered variables for drug 
assessment
Adapted from [14]
BI budgetary impact, CE cost-effectiveness, CU cost-utility












Time frames for treatment 
follow-up









Other modifications in use 
of resources linked to new 
treatment
Availability of CE or CU 
studies
Table 2  Decision rules for the definition of risk-sharing arrangements
BI budgetary impact, CSA cost-sharing arrangement, PLRS performance-linked reimbursement scheme, PBRSA performance-based risk-sharing 
arrangement




Limit and share the risk over short-term, medium-term, and 
long-term health outcomes





Limit and share the risk of unexpected growth of estimated BI 
due to variations in posology or treatment duration
CSA (e.g., price volume, budget and/or utilization capping) 
or conventional payment with simple discount based on 
clinical outcomes
Limit and share the risk of unexpected growth of estimated BI 
due to unforeseen use extensions and the patient population
CSA (e.g., price volume, budget or/and utilization capping), 
conventional payment with simple discount based on clini-
cal outcomes and/or access restriction concerning patient 
subgroups
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From 2016 to 2019, hospitals willing to participate in a 
PBRSA were required to sign additional contracts (i.e., adhe-
sion contracts) with the MAH and inform CatSalut about 
their involvement. Incentives to adhere to PBRSAs included 
the potential savings generated from the arrangements (i.e., 
discounts and refunds for non-responsive patients in PBR-
SAs where the treatment was fully or partially paid by the 
manufacturer), but also the opportunity to promote the use 
of medicines best fit for patients as a result of stricter RSA 
terms. However, the establishment of a RSA did not nec-
essarily penalize the pre-specified conditions of use and 
access established by the CFT-SISCAT for these medicines. 
Under certain circumstances (e.g., insufficient evidence on 
efficacy), the hospital’s decision to not adhere to the RSA 
or the dismissal of the RSA proposal by the manufacturer 
prompted a shift in these conditions of use towards use under 
exceptional use, which could have a detrimental effect on 
hospitals’ budgets. Over the 2016–19 period, 44 reference 
hospitals out of the 57 reference hospitals allowed to par-
ticipate in PBRSAs signed adhesion contracts with MAHs 
(77.2% adhesion rate).
3  RSAs: Implementation and Follow‑Up
The implementation of PBRSAs and CSAs in Catalonia has 
been largely supported by the use of patient registries and 
online databases to monitor drug use and cost [21, 22].
3.1  Monitoring Tools: Patient and Hospital 
Outpatient Drugs Treatment Registry 
and Invoicing for Health Services Application
The Patient and Hospital Outpatient Drugs Treatment Reg-
istry (RPT-MHDA, its Catalan acronym) is a broad, spe-
cific, and centralized online registry for all SISCAT hospi-
tals designed to systematically collect information on the 
use of innovative hospital outpatient drugs under conditions 
of routine clinical practice [21]. The RPT-MHDA provides 
information on (a) basic patient data (i.e., personal identi-
fication code, age, sex), (b) treatment (i.e., drug identifica-
tion, therapeutic indication, initiation and termination date, 
prescribing hospital), (c) baseline patient characteristics, (d) 
follow-up clinical variables, and (e) discontinuation vari-
ables [21]. These variables provide the necessary informa-
tion to assess compliance with the RSA criteria.
The Invoicing for Health Services Application (FSS, its 
acronym in Catalan) is an online database that monitors hos-
pital outpatient drugs expenditure by registering and collect-
ing billing data from each hospital and patient on a monthly 
Fig. 1  Risk-sharing arrangement (RSA) development process. 
CAMAPCE Consell Assessor de Medicaments d’Atenció Primària i 
Comunitària i Atenció Especialitzada (advisory council for primary 
care drugs), CAMH Consell Assessor de Medicació Hospitalària 
(advisory council for hospital outpatient drugs), CFT-SISCAT Comis-
sió Farmacoterapèutica per al Sistema Sanitari Integral d’Utilització 
Pública de Catalunya (decision-making commission), MAH market-
ing authorization holder, PHF Programa d’Harmonització Farma-
coterapèutica (drug appraisal program), WG working group
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basis [22]. The FSS includes variables on (a) patient identi-
fication (i.e., personal identification code, age, sex) and (b) 
hospital outpatient drug treatment (i.e., drug identification, 
dispensation or billing date, units, cost) [23]. Both databases 
are shared between hospitals and CatSalut, from which data 
are retrieved and presented in a spreadsheet-like format that 
facilitates data analysis.
3.2  Data Analysis
Data analysis is performed according to standards of obser-
vational studies [24, 25] and internal standard operating 
procedures. For PBRSAs, clinical data are retrieved via 
RPT-MHDA by identifying and selecting the study cohort 
according to the criteria defined in the agreement for the 
period under evaluation. Patients who do not meet the RSA 
criteria (i.e., eligible patient characteristics, measure of treat-
ment response at established time points, without missing 
variables or registry errors) are excluded from the scheme. 
According to the treatment variables, patients are classified 
into one of four subgroups: (a) responsive (i.e., treatment 
variables meet contractual definition of clinical response), 
(b) non-responsive (i.e., treatment variables do not meet con-
tractual definition of clinical response), (c) awaiting results 
(i.e., patients who have not yet reached the point for treat-
ment follow-up), and (d) others (i.e., patients who discon-
tinue the treatment because of reasons that are not covered 
by the agreement, for instance by patient’s choice). Prelimi-
nary results are sent to the respective hospitals, which are 
required to validate or amend their patients’ data via the 
online registry, and clarify any remaining doubts if needed. 
Descriptive analyses of health outcomes are performed with 
the validated data to assess: (a) patient demographic and 
baseline characteristics, (b) percentage of each patient cat-
egory, and (c) treatment response rate. Descriptive analy-
ses of economic consequences for PBRSAs and CSAs are 
conducted, considering the cost of total expenses and sav-
ings during the study period. Data on drug expenditure and 
invoiced drug quantities per each patient are retrieved and 
analyzed from the FSS. Limitations include the inability to 
analyze patient data that has not been registered by hospitals 
and/or has been introduced past the date of data collection.
3.3  Qualitative Analysis: Follow‑up Committees
Follow-up committees for PBRSAs and CSAs are com-
posed of CatSalut professionals, representatives of 
healthcare providers, and representatives of the MAH. In 
addition, follow-up committees for PBRSAs also include 
clinical experts in the therapeutic area. Every RSA has 
its own unique follow-up committee and the meetings 
are usually scheduled annually for standard year-to-year 
contracts.
The purpose of the follow-up meetings is to inform the 
MAH about the economic figures obtained for each RSA 
and the corresponding payments or refunds due to Cat-
Salut according to the agreed terms. These are defined by 
the total drug cost for non-responsive cases for PBRSAs 
and paybacks generated through the establishment of eco-
nomic agreements (e.g., fix discounts, expenditure ceilings) 
for CSAs. For PBRSAs, these meetings are also intended 
to share data on health outcomes and discuss the achieved 
results and overall experience of the parties involved (i.e., 
difficulties and areas for improvement spotted in the pro-
cess). This step is particularly important for drugs whose 
PBRSA results seem to differ with the evidence based on 
pivotal clinical trials, PBRSAs in which an improvement of 
the clinical pathway could facilitate their implementation 
(e.g., by increasing the efficiency or availability of imaging 
resources), and/or PBRSAs where the agreed terms seem 
to not be in line with the daily clinical practice (e.g., there 
is a need to extend the period of time required to measure 
treatment response).
Descriptive analyses on health and financial outcomes are 
shared with manufacturers prior to the invoicing process. 
However, the results of these analyses are aggregated (i.e., 
by hospital and as a sum of all the participating hospitals) 
for anonymization purposes. Only CatSalut has full access 
to individualized patient data regarding each RSA. Hospi-
tal access is restricted to patients who have been treated in 
their facilities. Manufacturers do not have access to patients’ 
data, in alignment with the European General Data Protec-
tion Regulation [26].
Based on the shared insights and conclusions reached by 
the follow-up committee, members propose next steps and 
actions aimed at deciding the future of each RSA. These 
can include decisions to: (a) add, withdraw, and/or amend 
any contractual clauses to better adjust treatment conditions 
or physician preferences to real-life practice (e.g., change 
of treatment response variable); (b) extend the agreement’s 
validity period for an additional year (up to 4 years) if all 
parties are satisfied with previous experience and further 
evidence is still required; or (c) terminate the agreement if 
considered appropriate (e.g., the obtained data resolve the 
uncertainty that motivated the RSA). The renewal rate for 
RSAs established over the 2016–19 period was 73.3%.
Moreover, upon the termination of a PBRSA and after 
the assessment of health outcomes, it is common practice 
to consider the need to negotiate a simple discount with the 
MAH that reflects the results, such as the unresponsiveness 
rate, acquired in real life during the course of the PBRSA. 
This offers the opportunity to further adjust the cost of the 
innovation covered by CatSalut according to the value the 
medicine has delivered in real-life clinical practice, thus 
bringing the price closer to the effectiveness observed in 
our setting for the specific indication under study. Hence, 
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the economic conditions of the new agreement are linked 
to the value of the medicine [27]. Such negotiations are, 
nonetheless, based on trust and cooperativity between the 
parts and under no circumstance discounts are mandatorily 
and/or unilaterally applied on these medicines.
Results, discussion points, and agreed next steps for each 
RSA are formally compiled in a confidential post-meeting 
report that is shared internally with the working group and 
presented to the CFT-SISCAT.
4  Lessons Learned from the Experience 
in Catalonia
After nearly 10 years of experience, 12 hospital-initiated 
pilots, and 15 RSAs led by CatSalut (eight PBRSAs and 
seven CSAs) across SISCAT, on balance, the feedback has 
been positive from all participating stakeholders. The 15 
RSAs implemented between 2016 and 2019 included 3017 
patients across Catalonia. The introduction of these schemes 
has encouraged a working dynamic that links the existing 
drug appraisal process with reimbursement models, provid-
ing an opportunity to assess the real-word clinical and finan-
cial performance of new drugs in a controlled setting [14]. 
This has ultimately led to the sustainable incorporation of 
innovation for patients under conditions that are considered 
optimal by payers, clinicians, and manufacturers [13]. The 
potential benefits of agreements that involve a risk-sharing 
element have not only come from gains in savings (2.4 M€ 
worth of refunds made by MAHs for all RSAs implemented 
between 2016 and 2019, representing a 3.8% of the total 
spending on medicines subject to RSAs throughout this 
period), but most importantly, from a more efficient use of 
medicines and the ability to identify, reduce, and share initial 
uncertainties on clinical outcomes and/or financial impact in 
the real world among participants.
Risk-sharing arrangement-generated real-world data 
have proven to be a powerful feedback tool used by deci-
sion makers to contrast and assess the alignment between 
real-world evidence and clinical trials [8, 10]. Moreover, in 
the long term, data generated from the implementation of 
such schemes have contributed, in some cases, to transform 
quantified uncertainties into actual discounts for payers and 
providers, helping to modulate targets according to real-
world insights. In Catalonia, PBRSA-generated real-world 
data have been used to re-assess and modify CFT-SISCAT’s 
recommendations and conditions of use for some of these 
medicines (12.5% of PBRSAs performed between 2016 and 
2019). As for manufacturers, RSAs constitute an opportunity 
to gather experience and real-world data on their products, 
as well as a chance to learn about new methods and mecha-
nisms to promote access for additional innovations in the 
future.
The successful establishment of RSAs in Catalonia has 
entailed a number of associated challenges and costs in 
terms of staff time, information technology, and diagnostic 
resources. Associated costs for these are unclear as all of 
these assets are not exclusive to RSAs. However, a proof of 
concept for the feasibility of establishing valid and efficient 
evidence collection processes through good professional 
practices to assess acceptable levels of uncertainty has suc-
cessfully been established.
Our experience has shown that being in possession of 
reliable, functioning, and well-suited databases for the col-
lection of clinical and financial data of medicines included 
in RSAs is the first and most important step, also a limiting 
factor, to securing a successful RSA implementation. The 
more standardized and systematic the process of data col-
lection is, the timelier, more simplified, and trustworthy will 
be the analysis.
Risk-sharing arrangements should always strive for 
clinical robustness and plausibility, appropriate real-world 
context, and easy monitoring of outcomes [7, 10, 28]. The 
design and implementation of RSAs require a well-thought-
out approach from the start, clear governance structures, and 
the commitment of all stakeholders. It is critical that the 
study design and the evidence being generated from RSAs 
are sufficient to address the uncertainties that are making 
payers reluctant to reimburse or recommend the drug in both 
quantitative and qualitative terms (i.e., backed by data analy-
sis and stakeholders’ expertise) [10].
To improve and optimize the overall RSA process, the 
working group has been refining its procedures to facilitate 
the implementation, analysis, and understanding of RSAs at 
regional and hospital levels. Steps have been taken towards 
avoiding interference in data analyses (e.g., by redefining 
and creating new treatment variables) and minimizing the 
administrative burden, by improving RPT-MHDA usability, 
performance, and overall quality [21], providing training to 
healthcare professionals, and creating protocols to ensure 
traceable and systematic data analyses, with the incorpora-
tion of preliminary information cross-checks with participat-
ing hospitals.
Last, our experience has demonstrated that a final evalu-
ation of the long-term impact of each RSA on the overall 
healthcare system’s efficiency, involving the sharing of data 
and knowledge among healthcare professionals, payers, and 
MAHs is highly beneficial and key for the learning process. 
This multidimensional exercise allows for the assessment of 
many factors such as the impact on effectiveness, whether 
appropriate evidence was generated to reduce uncertainty 
and support decision making, whether budget and time 
were appropriate, and whether the governance arrangements 
worked well, while posing a valuable opportunity for sug-
gesting improvements and bringing an overall sense of pur-
pose among participants [10, 14]. In addition, our experience 
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has evinced that mutual trust between stakeholders is the 
mainstay for building cooperative relationships and navigat-
ing the unexpected events that can emerge from these access 
schemes (e.g., change in pricing and reimbursement condi-
tions, modifications on CFT-SISCAT criteria for use based 
on an updated appraisal).
5  Areas for Improvement and Future 
Challenges
As prices of innovative drugs continue to rise and uncertain-
ties related to immature data at approval time are frequently 
present, the more relevant and challenging it becomes to 
improve and adapt existing RSA methodologies to ensure 
access while mitigating uncertainty, balancing clinical need 
with affordability [10, 17]. It is important to persevere at 
streamlining the bureaucratic process, maximizing patient 
access to healthcare resources, and promoting the involve-
ment and debate of healthcare professionals through edu-
cational activities and/or international conventions to fos-
ter connectivity. It is essential to implement good research 
practices that are results oriented and able to adapt to new 
situations and treatments that require different and changing 
clinical and economic set-ups [10]. An example of this could 
be the establishment of joint RSAs for competing products in 
the same indication or the establishment of RSAs for multi-
indication medicines. In our experience on the latter, Cat-
Salut has established CSAs for multi-indication products in 
cases where the drug was linked to economic uncertainty, by 
establishing a fixed discount for the product across its range 
of connected indications. However, for multi-indication 
products in which specific indications were linked to clini-
cal uncertainty, CatSalut has opted for the establishment of 
indication-specific PBRSAs, thus treating each indication 
separately.
Because of the considerable academic input during the 
creation of our RSA guideline, some recommendations, 
especially those targeting economic evaluations, were 
framed in a more academic set-up, reflecting an ideal sce-
nario where all clinical evidence and economic parameters 
(i.e., incremental CE and/or cost-utility ratios, willingness to 
pay) were known and available to the payers. However, the 
reality has been that not all of these data have been available 
to the payers at the time of decision making. Therefore, there 
is a need to seek further alignment between the theoretical 
methodology captured in our guidelines and the day-to-day 
reality of operating such entry arrangements. In this sense, 
steps have been taken towards a wider applicability of com-
plete economic evaluations as part of the routine appraisal 
process by the PHF in Catalonia.
It would also be interesting to determine whether public 
healthcare systems could benefit from extending the scope of 
RSAs to primary care drugs. However, from our experience, 
existing co-payment hurdles for these drugs, their generally 
large target populations, and their significantly lower levels 
of BI—at least in terms of cost per patient—make it diffi-
cult to implement innovative contracting strategies such as 
PBRSA for their access. Likewise, there is an ongoing inter-
national debate about whether the incorporation of patient-
reported outcomes in addition to clinical response criteria in 
PBRSA, which are currently not captured in routine clinical 
practice, could also be appropriate [28].
6  Conclusions
More than ever, healthcare systems require flexible models 
that allow alignment between the price of medicines and 
the value they deliver in treating patients. The increasing 
availability of costly innovative therapies associated with 
clinical and economic uncertainties has made RSAs a rea-
sonable response to increasing pressure for greater evidence 
of real-world effectiveness and CE. Thus, CatSalut has set up 
a systematic, traceable, and transparent methodology for the 
design and implementation of RSAs and 15 of such access 
schemes have been successfully implemented until Decem-
ber 2019. Our experience has acknowledged the need for 
a robust study design, appropriate financial, technical and 
administrative resources, and strong stakeholder commit-
ment and communication as critical to the success of RSAs. 
There are many reasons to be optimistic about the potential 
of these schemes as a key tool to promote sustainable access 
of medicines in the current budget-constrained climate; how-
ever, this is often undermined by the lack of transparency 
surrounding these schemes and the scant information that is 
available regarding national or regional experiences. Fur-
ther studies assessing the methodology, implementation, and 
impact of RSAs should be conducted and shared to address 
this obstacle.
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